Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
Terminated
The purpose of this study is to determine the safety and tolerability of dasatinib with bortezomib in the treatment of relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2017
Locations: Orlando Health, Inc. M.D. Anderson Cancer Center Orlando, Orlando, Florida +6 locations
Conditions: Multiple Myeloma
A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
Completed
This open-label trial will evaluate the use of lenalidomide; melphalan; and dexamethasone (MDR) to treat newly diagnosed or relapsed AL amyloidosis, over the course of nine 28-day cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2017
Locations: Stanford University Cancer Institute, Stanford, California
Conditions: Leukemia, Amyloidosis
Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy
Completed
We hypothesize that the combination of aprepitant with dexamethasone will provide significantly improved prophylaxis against Postoperative nausea and vomiting compared with the combination of ondansetron and dexamethasone, in patients undergoing craniotomy under general anesthesia.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/31/2017
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Postoperative Nausea and Vomiting
UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination
Withdrawn
The purpose of this study is to determine the efficacy of Ixazomib when combined with Pomalidomide and Dexamethasone, in terms of overall response rate in subjects with relapsed Multiple Myeloma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2017
Locations: University of Arkansas for Medical Science, Little Rock, Arkansas
Conditions: Multiple Myeloma
Multi-day Doses in Prevention of Nausea and Emesis
Completed
To assess emetic responses to multi-day doses of Palonosetron and Aprepitant and low dose dexamethasone +/- Prochlorperazine among patients with multiple myeloma and lymphoma undergoing autologous HSCT utilizing the Multinational Association for Supportive Care in Cancer (MASCC) Antiemesis Tool (MAT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/18/2017
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Myeloma, Plasma-Cell, Lymphoma, Malignant
Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
Completed
This trial evaluated the safety of combining bevacizumab and pemetrexed in non-small cell lung cancer (NSCLC) patients with stable brain metastases as second-line chemotherapy, while evaluating progression-free survival (PFS) and overall survival (OS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2017
Locations: Stanford University School of Medicine, Stanford, California +3 locations
Conditions: Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Neoplasm Metastasis
CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Completed
RATIONALE: Drugs such as CC-5013 and dexamethasone may be effective in treating primary systemic amyloidosis. PURPOSE: This phase II trial is studying CC-5013 to see how well it works with or without dexamethasone in treating patients with primary systemic amyloidosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/28/2016
Locations: Cancer Research Center at Boston Medical Center, Boston, Massachusetts
Conditions: Multiple Myeloma
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Completed
RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of abnormal plasma cells, either by killing the cells or by stopping them from dividing. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop the abnormal plasma cells from growing. Giving melphalan together with lenalidomide and dexamethasone may be an effective treatment for primary systemic amyloidosis. PURPOSE: This phase II... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/28/2016
Locations: Boston University Cancer Research Center, Boston, Massachusetts
Conditions: Multiple Myeloma
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
Completed
Open-label, Phase II study of Stomatitis prevention with a steroid-based mouthwash in Post-menopausal women with ER+, HER2- Metastatic or Locally Advanced Breast Cancer
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/20/2016
Locations: Highlands Oncology Group Highlands Oncology Group (22), Fayetteville, Arkansas +22 locations
Conditions: Advanced Breast Cancer
Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
Withdrawn
This phase II trial studies how well carfilzomib and dexamethasone work in treating patients with multiple myeloma who previously underwent a stem cell transplant. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunosuppressive therapy, such as dexamethasone, may improve bone marrow function and increase blood cell counts. Giving carfilzomib together with dexamethasone may be an effective treatment for multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/15/2016
Locations: City of Hope, Duarte, California +2 locations
Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Completed
The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in patients with stage IIIB, IV or recurrent NSCLC. Safety information about BIBF1120/pemetrexed will be obtained.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/08/2016
Locations: Boehringer Ingelheim Investigational Site, Downy, California +166 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Early Treatment With Dexamethasone in Mild Acute Pancreatitis
Withdrawn
This pilot trial will evaluate the following in patients with acute pancreatitis: 1. Safety profile of early treatment with intravenous dexamethasone 2. Impact of dexamethasone on systemic inflammation in patients with acute pancreatitis 3. Provide preliminary data on potential impact of early treatment with steroids on clinical outcomes
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/08/2016
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Patients With Acute Pancreatitis